MARKET

APLS

APLS

Apellis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.30
+1.39
+4.36%
After Hours: 33.30 0 0.00% 16:00 07/15 EDT
OPEN
32.12
PREV CLOSE
31.91
HIGH
33.86
LOW
31.88
VOLUME
470.83K
TURNOVER
--
52 WEEK HIGH
45.04
52 WEEK LOW
16.85
MARKET CAP
2.51B
P/E (TTM)
-4.6506
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average APLS stock price target is 53.80 with a high estimate of 86.00 and a low estimate of 30.00.

EPS

APLS News

More
Apellis Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 6d ago
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 07/07 21:05
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4); Exercise Price Of $31.96
Benzinga · 07/07 20:06
Apellis advances late-stage studies of pegcetacoplan in vision loss disorder
Seeking Alpha - Article · 07/07 11:44
Apellis Completes Enrollment In Two Phase 3 Studies Of Targeted C3 Therapy, Pegcetacoplan, In Patients With Geographic Atrophy
Pivotal Phase 3 DERBY and OAKS studies enrolled a total of 1,259 patients   Top-line results expected in Q3 2021   Pegcetacoplan targets C3 to control the irreversible lesion growth in
Benzinga · 07/07 11:04
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
Apellis Pharmaceuticals Inc., (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it completed enrollment in the Phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan (APL-2), a targeted C3 therap
GlobeNewswire · 07/07 11:00
PolyPid Phase 3 And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/05 07:31
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
GlobeNewswire · 07/02 13:00

Industry

Pharmaceuticals
+1.75%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About APLS

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.
More

Webull offers kinds of Apellis Pharmaceuticals Inc stock information, including NASDAQ:APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.